Although the markets declined slightly in 2010, they are expected to reach $2 billion by 2017.Within the cardiac rhythm management (CRM), electrophysiology and ablation device report, companies such as Boston Scientific, Cardiac Science, Medtronic, Sorin Group and St. Jude Medical lead the market, among many others.